Equillium(EQ) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights $32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients, representing the first of two data sets that will trigger Ono Pharmaceutical’s option exercise decision for itolizumab, expected in 2H 2024 LA JOLLA, California, May 9, 2024 – Equillium Inc. (Nasdaq: EQ), a ...